ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Without the ddPCR platform and commercial qPCR assays, the MRD monitoring of CML patient habouring BCR::ABL1 e19a2 was only achievable by a qualitative conventional PCR with a sensitivity of around 10–3 to 10–413,14.